keyword
MENU ▼
Read by QxMD icon Read
search

Fidaxomicin

keyword
https://www.readbyqxmd.com/read/28077203/clostridium-difficile-infection-in-older-adults-systematic-review-of-efforts-to-reduce-occurrence-and-improve-outcomes
#1
Leisa L Marshall, Samuel Peasah, Gregg A Stevens
OBJECTIVE: Provide a systematic review of the primary literature on efforts to reduce Clostridium difficile infection (CDI) occurrence and improve outcomes in older adults. DATA SOURCES, STUDY SELECTION, DATA EXTRACTION: PubMed and CINAHL databases were searched for research studies using search terms CDI, CDI prevention, reduction, control, management, geriatric, elderly, adults 65 years of age and older. The MeSH categories Aged and Aged, 80 and older, were used...
January 1, 2017: Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists
https://www.readbyqxmd.com/read/28027991/successful-treatment-of-severe-clostridium-difficile-infection-by-administration-of-crushed-fidaxomicin-via-a-nasogastric-tube-in-a-critically-ill-patient
#2
Sven Arends, Jerome Defosse, Cori Diaz, Frank Wappler, Samir G Sakka
OBJECTIVE: To report the successful use of crushed fidaxomicin via a nasogastric tube for treatment of a severe Clostridium difficile infection in a critically ill patient. DATA SOURCES: Clinical observation of a patient, images of abdominal computed tomography, antimicrobial therapy and course of infection parameters. DATA EXTRACTION: Relevant information contained in the medical observation of the patient and selection of image and laboratory parameters performed in the patient...
December 24, 2016: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/28009682/outcomes-with-fidaxomicin-therapy-in-clostridium-difficile-infection
#3
Clayton M Spiceland, Sahil Khanna, Darrell S Pardi
BACKGROUND AND GOALS: Fidaxomicin is a new antibiotic used to treat Clostridium difficile infection (CDI). Given limited clinical experience with fidaxomicin, we assessed outcomes in a diverse cohort of patients with CDI treated with fidaxomicin. STUDY: All CDI cases treated with fidaxomicin at 3 referral centers over a 4-year period were included. Response was defined as resolution of diarrhea and recurrence was defined by recurrence of CDI within 8 weeks of the end of treatment...
December 22, 2016: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/27993853/in-vitro-activities-of-mcb3681-and-8-comparators-against-clostridium-difficile-isolates-with-known-ribotypes-and-diverse-geographical-spread
#4
J Freeman, S Pilling, J Vernon, M H Wilcox
Treatments for Clostridium difficile infection remain limited, despite the introduction of fidaxomicin, and development of new agents is necessary.We determined the in vitro susceptibilities of 199 prevalent or emerging Clostridium difficile PCR ribotypes to MCB3681, a novel investigational quinolonyl-oxazolidinone, and 8 comparators (metronidazole, vancomycin, fidaxomicin, moxifloxacin, ciprofloxacin, clindamycin, tigecycline and linezolid).MCB3681 showed good activity against C. difficile with no evidence of MCB3681 resistance in isolates showing either or both moxifloxacin and linezolid resistance...
December 19, 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27978522/successful-therapy-of-severe-pseudomembranous-clostridium-difficile-colitis-using-combination-of-fecal-microbiota-therapy-and-fidaxomicin
#5
Peter Konturek, Drilon Haziri, Harry Helfritzsch, Thomas Hess, Steffen Heymann, Igor Harsch
No abstract text is available yet for this article.
December 15, 2016: Medical Principles and Practice: International Journal of the Kuwait University, Health Science Centre
https://www.readbyqxmd.com/read/27971328/cost-effectiveness-analysis-of-fidaxomicin-versus-oral-vancomycin-for-the-treatment-of-clostridium-difficile-infection-in-egypt
#6
M Hossam, G Elsisi
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27917075/management-of-clostridium-difficile-infection
#7
Layth S Al-Jashaami, Herbert L DuPont
Since the discovery of Clostridium difficile infection (CDI) in the 1970s, there has been an increase in the incidence, severity, and recurrence rate of the disease. We reviewed the recent CDI literature in PubMed published before February 28, 2016 that focused on advances in therapy. Despite a large number of studies describing methods for diagnosing the disease, there is currently no definitive test that identifies this infection with certainty, which complicates therapy. Recommended therapy for CDI includes oral metronidazole for mild cases and oral vancomycin or fidaxomicin for moderate to severe cases, each given for 10 to 14 days...
October 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27896376/reducing-the-bottleneck-in-discovery-of-novel-antibiotics
#8
Marcus B Jones, William C Nierman, Yue Shan, Bryan C Frank, Amy Spoering, Losee Ling, Aaron Peoples, Ashley Zullo, Kim Lewis, Karen E Nelson
Most antibiotics were discovered by screening soil actinomycetes, but the efficiency of the discovery platform collapsed in the 1960s. By now, more than 3000 antibiotics have been described and most of the current discovery effort is focused on the rediscovery of known compounds, making the approach impractical. The last marketed broad-spectrum antibiotics discovered were daptomycin, linezolid, and fidaxomicin. The current state of the art in the development of new anti-infectives is a non-existent pipeline in the absence of a discovery platform...
November 28, 2016: Microbial Ecology
https://www.readbyqxmd.com/read/27876339/diagnosis-and-treatment-of-clostridium-difficile-c-diff-colitis-review-of-the-literature-and-a-perspective-in-gynecologic-oncology
#9
REVIEW
Kristin N Taylor, Michael T McHale, Cheryl C Saenz, Steven C Plaxe
Clostridium difficile infection (CDI) is a major cause of nosocomial diarrhea with the potential for significant morbidity and mortality. Colonization in a susceptible individual, with risk factors such as prior antibiotic use, advanced age, or medical comorbidities, may result in symptomatic infection. Although patients with a gynecologic malignancy may be at a higher risk of developing CDI due to an increased likelihood of having one or more risk factors, data do not consistently support the idea that chemotherapy or cancer itself are independently associated with CDI...
November 19, 2016: Gynecologic Oncology
https://www.readbyqxmd.com/read/27862113/rethinking-strategies-to-select-antibiotic-therapy-in-clostridium-difficile-infection
#10
Teena Chopra, Ellie J C Goldstein, Sherwood L Gorbach
In recent years, Clostridium difficile infection (CDI) has become a global public health threat associated with increased morbidity, mortality, and economic burden, all of which are exacerbated with disease recurrence. Current guidelines informing treatment decisions are largely based on definitions of disease severity at diagnosis, with subjective components not well delineated across treatment algorithms and clinical trials. Furthermore, there is little evidence linking severity at onset to outcome. However, reducing the risk of recurrence may offer both a better outcome for the individual and decreased downstream economic impact...
December 2016: Pharmacotherapy
https://www.readbyqxmd.com/read/27796474/-clostridium-difficile-infection-what-is-currently-available-for-treatment
#11
A Stallmach
Clostridium difficile (C. difficile) is an anaerobic, Gram-positive, spore-forming, toxin-secreting bacillus. It is transmitted via a fecal-oral route and can be found in 1-3 % of the healthy population. Symptoms caused by C. difficile range from uncomplicated diarrhea to a toxic megacolon. The incidence, frequency of recurrence, and mortality rate of C. difficile infections (CDIs) have increased significantly over the past few decades. The most important risk factor is antibiotic treatment in elderly patients and patients with severe comorbidities...
December 2016: Der Internist
https://www.readbyqxmd.com/read/27785569/-clostridium-difficile-infections-in-geriatric-patients
#12
R Simmerlein, A Basta, M Gosch
Clostridium difficile is the main cause of nosocomial antibiotic-associated diarrhea in adults in Europe and North America. Infections with C. difficile typically occur in elderly patients with comorbidities and prior antibiotic therapy. Other risk factors are proton pump inhibitors, which are taken by many elderly patients. The main virulence factors are toxins A and B. The clinical spectrum ranges from asymptomatic colonization to severe disease with abdominal complications and sepsis. The current diagnostic gold standard is anaerobic culture but is impractical in routine use due to the long duration...
December 2016: Zeitschrift Für Gerontologie und Geriatrie
https://www.readbyqxmd.com/read/27770261/epidemiology-and-recurrence-rates-of-clostridium-difficile-infections-in-germany-a-secondary-data-analysis
#13
Christoph Lübbert, Lisa Zimmermann, Julia Borchert, Bernd Hörner, Reinier Mutters, Arne C Rodloff
INTRODUCTION: Clostridium difficile infection (CDI) is the most common cause of health-care-associated infectious diarrhea. Recurrence rates are as high as 20-30% after standard treatment with metronidazole or vancomycin, and appear to be reduced for patients treated with fidaxomicin. According to the literature, the risk of CDI recurrence increases after the second relapse to 30-65%. Accurate data for Germany are not yet available. METHODS: Based on the research database of arvato health analytics (Munich, Germany), a secondary data analysis for the incidence, treatment characteristics and course of CDI was performed...
December 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27718071/the-efficacy-of-fidaxomicin-in-the-treatment-of-clostridium-difficile-infection-in-a-real-world-clinical-setting-a-spanish-multi-centre-retrospective-cohort
#14
C Fehér, E Múñez Rubio, P Merino Amador, A Delgado-Iribarren Garcia-Campero, M Salavert, E Merino, E Maseda Garrido, V Díaz-Brito, M J Álvarez, J Mensa
The objective of this study was to evaluate the efficacy and safety of fidaxomicin in the real-life clinical setting. This was a retrospective cohort of patients with Clostridium difficile infection (CDI) treated with fidaxomicin in 20 Spanish hospitals between July 2013 and July 2014. Clinical cure, 30-day recurrence, 30-day mortality, sustained cure, and factors associated with the failure to achieve sustained cure were analyzed. Of the 72 patients in the cohort 41 (56.9 %) had a fatal underlying disease...
October 8, 2016: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/27664230/faecal-microbiota-transplantation-for-recurring-clostridium-difficile-infection-in-a-patient-with-crohn-s-disease-and-ileorectal-anastomosis
#15
Asser Mathiassen Oppfeldt, Jens F Dahlerup, Lisbet A Christensen, Christian L Hvas
Faecal microbiota transplantation (FMT) is increasingly being used to treat refractory and recurring Clostridium difficile infection (CDI). Although FMT appears to be safe and highly effective in patients with a preserved colon and immunocompetence, its use in patients with inflammatory bowel disease (IBD) who are on immunomodulating therapies is controversial. In particular, patients who have undergone colectomy may have different treatment responses to FMT. In this case report, we describe the successful use of FMT in a female patient aged 19 years with Crohn's disease who underwent ileorectal anastomosis following colectomy...
2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27606976/the-epidemiology-of-clostridium-difficile-infection-in-patients-with-cancer
#16
Andrew I T Hebbard, Monica A Slavin, Caroline Reed, Benjamin W Teh, Karin A Thursky, Jason A Trubiano, Leon J Worth
Clostridium difficile infection (CDI) is a significant cause of healthcare-associated diarrhoea, and the emergence of endemic strains resulting in poorer outcomes is recognised worldwide. Patients with cancer are a specific high-risk group for development of infection. Areas covered: In this review, modifiable and non-modifiable risk factors for CDI in adult patients with haematological malignancy or solid tumours are evaluated. In particular, the contribution of antimicrobial exposure, hospitalisation and gastric acid suppression to risk of CDI are discussed...
November 2016: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/27601193/-a-scoring-system-for-prescribing-fidaxomicin-in-clostridium-diff%C3%A3-cile-infection
#17
María Jesús Vivancos-Gallego, M Ángeles Jiménez-López, Francesca Gioia, Dione Ibañez-Segura, José Romero-Vivas, Javier Cobo
Recurrences of Clostridium difficile infections lead to hospital readmissions and high costs, in addition to the suffering and frustration for the patients. Fidaxomicin has recently been introduced as a new antibiotic that has been shown to significantly reduce the recurrence of this infection. Despite this superiority, its high cost has led to very restrictive policies in its use, as such that many institutions only use it in patients with multiple recurrences. While waiting for new predictive clinical tools, we propose the development of scoring systems that allow the more high-risk patients to be treated earlier...
September 3, 2016: Enfermedades Infecciosas y Microbiología Clínica
https://www.readbyqxmd.com/read/27556739/association-of-fidaxomicin-with-c-difficile-spores-effects-of-persistence-on-subsequent-spore-recovery-outgrowth-and-toxin-production
#18
Caroline H Chilton, Grace S Crowther, Helen Ashwin, Chris M Longshaw, Mark H Wilcox
BACKGROUND: We have previously shown that fidaxomicin instillation prevents spore recovery in an in-vitro gut model, whereas vancomycin does not. The reasons for this are unclear. Here, we have investigated persistence of fidaxomicin and vancomycin on C. difficile spores, and examined post-antibiotic exposure spore recovery, outgrowth and toxin production. METHODS: Prevalent UK C. difficile ribotypes (n = 10) were incubated with 200mg/L fidaxomicin, vancomycin or a non-antimicrobial containing control for 1 h in faecal filtrate or Phosphate Buffered Saline...
2016: PloS One
https://www.readbyqxmd.com/read/27536508/a-multi-center-study-of-fidaxomicin-use-for-clostridium-difficile-infection
#19
Dhara N Shah, Fay S Chan, Nandita Kachru, Krutina P Garcia, Holly E Balcer, April P Dyer, John E Emanuel, Michelle D Jordan, Katherine T Lusardi, Geri Naymick, Radhika S Polisetty, Lanny Sieman, Ashley M Tyler, Michael L Johnson, Kevin W Garey
PURPOSE: Fidaxomicin use in real-world clinical practice, especially for severe Clostridium difficile infection (CDI), is mainly based on single-center observational studies. The purpose of this pharmacoepidemiology study was to assess outcomes of patients given fidaxomicin based on episode number and use of concomitant antibiotics. METHODS: Fidaxomicin use over time across included hospitals in the United States was assessed using a large inpatient drug utilization database...
2016: SpringerPlus
https://www.readbyqxmd.com/read/27536153/an-update-on-antibody-based-immunotherapies-for-clostridium-difficile-infection
#20
REVIEW
Greg Hussack, Jamshid Tanha
Clostridium difficile continues to be one of the most prevalent hospital-acquired bacterial infections in the developed world, despite the recent introduction of a novel and effective antibiotic agent (fidaxomicin). Alternative approaches under investigation to combat the anaerobic Gram-positive bacteria include fecal transplantation therapy, vaccines, and antibody-based immunotherapies. In this review, we catalog the recent advances in antibody-based approaches under development and in the clinic for the treatment of C...
2016: Clinical and Experimental Gastroenterology
keyword
keyword
23034
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"